Sadhana Jackson’s research on evaluating the blood-brain barrier of malignant gliomas – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
”CANCER CURRENTS: Sadhana Jackson, an adjunct investigator in our Pediatric Oncology Branch and an investigator in the Surgical Neurology Branch at the National Institute of Neurological Disorders and Stroke (NINDS), weighed in on the FDA granting accelerated approval to tovorafenib (Ojemda) for kids aged 6 months or older who have low-grade glioma, a type of brain tumor, with changes in a gene called BRAF.
Sadhana Jackson’s research interests center on evaluating the blood-brain barrier (BBB) of malignant gliomas. Her clinical and translational research focuses on transiently disrupting the BBB by pharmacologic means, in an effort to improve cytotoxic therapy to the central nervous system.
Sadhana Jackson also leads collaborative preclinical and clinical studies focused on understanding BBB integrity in normal brain and malignant gliomas with the goal of developing novel treatment strategies for brain tumor patients.”
